Eli Lilly and Company
LLY
$896.53
$33.673.90%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 18.41B | 13.80B | 11.11B | 10.59B | 8.37B |
| Total Depreciation and Amortization | 1.90B | 1.89B | 1.83B | 1.77B | 1.67B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.40B | 3.11B | 3.38B | 1.85B | 2.33B |
| Change in Net Operating Assets | -6.64B | -7.86B | -7.00B | -5.39B | -6.33B |
| Cash from Operations | 16.06B | 10.94B | 9.32B | 8.82B | 6.03B |
| Capital Expenditure | -6.79B | -6.05B | -5.58B | -5.06B | -4.63B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -549.40M | 0.00 | -947.70M | -947.70M | -1.99B |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.75B | -5.06B | -4.95B | -3.30B | -3.68B |
| Cash from Investing | -10.09B | -11.11B | -11.48B | -9.30B | -10.31B |
| Total Debt Issued | 13.17B | 11.43B | 11.43B | 11.42B | 16.01B |
| Total Debt Repaid | -2.07B | -1.07B | 840.10M | -2.52B | -5.56B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -4.65B | -4.39B | -3.70B | -2.50B | -446.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -5.21B | -5.03B | -4.86B | -4.68B | -4.53B |
| Other Financing Activities | -792.40M | -809.50M | -787.10M | -490.60M | -476.70M |
| Cash from Financing | 440.40M | 120.70M | 2.92B | 1.23B | 5.00B |
| Foreign Exchange rate Adjustments | 10.60M | 205.80M | -129.30M | -296.70M | 261.10M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.42B | 152.30M | 633.10M | 449.80M | 988.20M |